SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-011076
Filing Date
2024-08-06
Accepted
2024-08-06 16:02:30
Documents
76
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q crvs-20240630x10q.htm   iXBRL 10-Q 2028406
2 EX-31.1 crvs-20240630xex31d1.htm EX-31.1 11896
3 EX-31.2 crvs-20240630xex31d2.htm EX-31.2 11834
4 EX-32.1 crvs-20240630xex32d1.htm EX-32.1 11808
5 GRAPHIC crvs-20240630x10q007.jpg GRAPHIC 95099
  Complete submission text file 0001558370-24-011076.txt   8267461

Data Files

Seq Description Document Type Size
6 EX-101.SCH crvs-20240630.xsd EX-101.SCH 46132
7 EX-101.CAL crvs-20240630_cal.xml EX-101.CAL 52880
8 EX-101.DEF crvs-20240630_def.xml EX-101.DEF 193502
9 EX-101.LAB crvs-20240630_lab.xml EX-101.LAB 420007
10 EX-101.PRE crvs-20240630_pre.xml EX-101.PRE 336515
79 EXTRACTED XBRL INSTANCE DOCUMENT crvs-20240630x10q_htm.xml XML 1391820
Mailing Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010
Business Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010 (650) 900-4520
Corvus Pharmaceuticals, Inc. (Filer) CIK: 0001626971 (see all company filings)

IRS No.: 464670809 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37719 | Film No.: 241179014
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)